BRD2 and breast cancer: In the non-pCR group, the mean HIF1α expression ratio was 60.91, while in the pCR group, the mean HIF1α expression ratio was 39.22, which indicated that a high HIF1α expression may predict lower pCR rate to NAT for BC patients (Table 1).